210 related articles for article (PubMed ID: 26628527)
1. Study protocol for a phase III multicentre, randomised, open-label, blinded-end point trial to evaluate the efficacy and safety of immunoglobulin plus cyclosporin A in patients with severe Kawasaki disease (KAICA Trial).
Aoyagi R; Hamada H; Sato Y; Suzuki H; Onouchi Y; Ebata R; Nagashima K; Terauchi M; Terai M; Hanaoka H; Hata A;
BMJ Open; 2015 Dec; 5(12):e009562. PubMed ID: 26628527
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of primary treatment with immunoglobulin plus ciclosporin for prevention of coronary artery abnormalities in patients with Kawasaki disease predicted to be at increased risk of non-response to intravenous immunoglobulin (KAICA): a randomised controlled, open-label, blinded-endpoints, phase 3 trial.
Hamada H; Suzuki H; Onouchi Y; Ebata R; Terai M; Fuse S; Okajima Y; Kurotobi S; Hirai K; Soga T; Ishiguchi Y; Okuma Y; Takada N; Yanai M; Sato J; Nakayashiro M; Ayusawa M; Yamamoto E; Nomura Y; Hashimura Y; Ouchi K; Masuda H; Takatsuki S; Hirono K; Ariga T; Higaki T; Otsuki A; Terauchi M; Aoyagi R; Sato T; Fujii Y; Fujiwara T; Hanaoka H; Hata A;
Lancet; 2019 Mar; 393(10176):1128-1137. PubMed ID: 30853151
[TBL] [Abstract][Full Text] [Related]
3. Multi-centre, randomised, open-label, blinded endpoint assessed, trial of corticosteroids plus intravenous immunoglobulin (IVIG) and aspirin, versus IVIG and aspirin for prevention of coronary artery aneurysms (CAA) in Kawasaki disease (KD): the KD CAA prevention (KD-CAAP) trial protocol.
Eleftheriou D; Moraes YC; Purvis C; Pursell M; Morillas MM; Kahn R; Mossberg M; Kucera F; Tulloh R; Standing JF; Swallow V; McCormack R; Herberg J; Levin M; Wan M; Klein N; Connon R; Walker AS; Brogan P
Trials; 2023 Jan; 24(1):60. PubMed ID: 36703139
[TBL] [Abstract][Full Text] [Related]
4. Effects of immunoglobulin plus prednisolone in reducing coronary artery lesions in patients with Kawasaki disease: study protocol for a phase III multicenter, open-label, blinded-endpoints randomized controlled trial.
Lin SY; He L; Xie LP; Wang Y; Lin YX; Cao YY; Yan WL; Liu F; Huang GY
Trials; 2021 Dec; 22(1):898. PubMed ID: 34895290
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of intravenous immunoglobulin plus prednisolone therapy in patients with Kawasaki disease (Post RAISE): a multicentre, prospective cohort study.
Miyata K; Kaneko T; Morikawa Y; Sakakibara H; Matsushima T; Misawa M; Takahashi T; Nakazawa M; Tamame T; Tsuchihashi T; Yamashita Y; Obonai T; Chiga M; Hori N; Komiyama O; Yamagishi H; Miura M;
Lancet Child Adolesc Health; 2018 Dec; 2(12):855-862. PubMed ID: 30337183
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial.
Kobayashi T; Saji T; Otani T; Takeuchi K; Nakamura T; Arakawa H; Kato T; Hara T; Hamaoka K; Ogawa S; Miura M; Nomura Y; Fuse S; Ichida F; Seki M; Fukazawa R; Ogawa C; Furuno K; Tokunaga H; Takatsuki S; Hara S; Morikawa A;
Lancet; 2012 Apr; 379(9826):1613-20. PubMed ID: 22405251
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of intravenous immunoglobulin alone and intravenous immunoglobulin combined with high-dose aspirin in the acute stage of Kawasaki disease: study protocol for a randomized controlled trial.
Kuo HC; Guo MM; Lo MH; Hsieh KS; Huang YH
BMC Pediatr; 2018 Jun; 18(1):200. PubMed ID: 29933749
[TBL] [Abstract][Full Text] [Related]
8. Japanese POEMS syndrome with Thalidomide (J-POST) Trial: study protocol for a phase II/III multicentre, randomised, double-blind, placebo-controlled trial.
Katayama K; Misawa S; Sato Y; Sobue G; Yabe I; Watanabe O; Nishizawa M; Kusunoki S; Kikuchi S; Nakashima I; Ikeda S; Kohara N; Kanda T; Kira J; Hanaoka H; Kuwabara S;
BMJ Open; 2015 Jan; 5(1):e007330. PubMed ID: 25573527
[TBL] [Abstract][Full Text] [Related]
9. Treatment of acute Kawasaki disease: aspirin's role in the febrile stage revisited.
Hsieh KS; Weng KP; Lin CC; Huang TC; Lee CL; Huang SM
Pediatrics; 2004 Dec; 114(6):e689-93. PubMed ID: 15545617
[TBL] [Abstract][Full Text] [Related]
10. Kawasaki disease: a comprehensive review of treatment options.
Patel RM; Shulman ST
J Clin Pharm Ther; 2015 Dec; 40(6):620-5. PubMed ID: 26547265
[TBL] [Abstract][Full Text] [Related]
11. Different dose aspirin plus immunoglobulin (DAPI) for prevention of coronary artery abnormalities in Kawasaki disease: Study protocol for a multi-center, prospective, randomized, open-label, blinded end-point, non-inferiority trial.
Wu Y; Hu L; Xie X; Li W; Wang Y; Zhang L; Huang P; Li F; Li J; Xia S; Yuan J; Li M; Wang Z; Zhang X
Am Heart J; 2024 Jul; 273():1-9. PubMed ID: 38508571
[TBL] [Abstract][Full Text] [Related]
12. Clarithromycin Plus Intravenous Immunoglobulin Therapy Can Reduce the Relapse Rate of Kawasaki Disease: A Phase 2, Open-Label, Randomized Control Study.
Nanishi E; Nishio H; Takada H; Yamamura K; Fukazawa M; Furuno K; Mizuno Y; Saigo K; Kadoya R; Ohbuchi N; Onoe Y; Yamashita H; Nakayama H; Hara T; Ohno T; Takahashi Y; Hatae K; Harada T; Shimose T; Kishimoto J; Ohga S; Hara T
J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28684643
[TBL] [Abstract][Full Text] [Related]
13. High-Dose Aspirin is Associated with Anemia and Does Not Confer Benefit to Disease Outcomes in Kawasaki Disease.
Kuo HC; Lo MH; Hsieh KS; Guo MM; Huang YH
PLoS One; 2015; 10(12):e0144603. PubMed ID: 26658843
[TBL] [Abstract][Full Text] [Related]
14. Adjunct cyclosporine therapy for refractory Kawasaki disease in a very young infant.
Okada S; Azuma Y; Suzuki Y; Yamada H; Wakabayashi-Takahara M; Korenaga Y; Akase H; Hasegawa S; Ohga S
Pediatr Int; 2016 Apr; 58(4):295-8. PubMed ID: 26670024
[TBL] [Abstract][Full Text] [Related]
15. Inflammatory cytokine profiles during Cyclosporin treatment for immunoglobulin-resistant Kawasaki disease.
Hamada H; Suzuki H; Abe J; Suzuki Y; Suenaga T; Takeuchi T; Yoshikawa N; Shibuta S; Miyawaki M; Oishi K; Yamaga H; Aoyagi N; Iwahashi S; Miyashita R; Honda T; Onouchi Y; Terai M; Hata A
Cytokine; 2012 Dec; 60(3):681-5. PubMed ID: 22944461
[TBL] [Abstract][Full Text] [Related]
16. Early treatment with intravenous immunoglobulin in patients with Kawasaki disease.
Tse SM; Silverman ED; McCrindle BW; Yeung RS
J Pediatr; 2002 Apr; 140(4):450-5. PubMed ID: 12006960
[TBL] [Abstract][Full Text] [Related]
17. Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial.
Tremoulet AH; Jain S; Jaggi P; Jimenez-Fernandez S; Pancheri JM; Sun X; Kanegaye JT; Kovalchin JP; Printz BF; Ramilo O; Burns JC
Lancet; 2014 May; 383(9930):1731-8. PubMed ID: 24572997
[TBL] [Abstract][Full Text] [Related]
18. Timing of intravenous immunoglobulin treatment and risk of coronary artery abnormalities in children with Kawasaki disease.
Bal AK; Prasad D; Umali Pamintuan MA; Mammen-Prasad E; Petrova A
Pediatr Neonatol; 2014 Oct; 55(5):387-92. PubMed ID: 24636168
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and limitation of infliximab treatment for children with Kawasaki disease intractable to intravenous immunoglobulin therapy: report of an open-label case series.
Mori M; Imagawa T; Hara R; Kikuchi M; Hara T; Nozawa T; Miyamae T; Yokota S
J Rheumatol; 2012 Apr; 39(4):864-7. PubMed ID: 22337241
[TBL] [Abstract][Full Text] [Related]
20. High-dose versus low-dose intravenous immunoglobulin for treatment of children with Kawasaki disease weighing 25 kg or more.
Suzuki T; Michihata N; Yoshikawa T; Hata T; Matsui H; Fushimi K; Yasunaga H
Eur J Pediatr; 2020 Dec; 179(12):1901-1907. PubMed ID: 32862279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]